Louise Frederika Kooij Sells 34,400 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 34,400 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $32.78, for a total transaction of $1,127,632.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $798,291.34. This trade represents a 58.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.75, for a total value of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $31.88 on Thursday. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of -15.55 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The business’s 50-day moving average is $35.32 and its 200-day moving average is $31.25.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. Equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NAMS. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Citigroup upped their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. HC Wainwright initiated coverage on NewAmsterdam Pharma in a report on Monday, October 20th. They set a “buy” rating and a $52.00 price target for the company. The Goldman Sachs Group boosted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research note on Tuesday, December 2nd. Finally, Needham & Company LLC raised their price objective on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $47.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NAMS. Capital World Investors raised its stake in shares of NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after acquiring an additional 1,434,986 shares in the last quarter. Jennison Associates LLC grew its holdings in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Duquesne Family Office LLC raised its position in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after buying an additional 1,062,359 shares during the last quarter. Finally, Maverick Capital Ltd. lifted its stake in shares of NewAmsterdam Pharma by 178.8% in the second quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after buying an additional 982,405 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.